CO5540278A2 - Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion - Google Patents
Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacionInfo
- Publication number
- CO5540278A2 CO5540278A2 CO03111139A CO03111139A CO5540278A2 CO 5540278 A2 CO5540278 A2 CO 5540278A2 CO 03111139 A CO03111139 A CO 03111139A CO 03111139 A CO03111139 A CO 03111139A CO 5540278 A2 CO5540278 A2 CO 5540278A2
- Authority
- CO
- Colombia
- Prior art keywords
- agent
- alkaline
- formulation according
- formulation
- meglumine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Una formulación farmacéutica de sabor enmascarado, cuyo enmascaramiento persiste tras la administración de la formulación, especialmente en forma de suspensión en un vehículo acuoso, caracterizada porque comprende al menos los siguientes elementos:a) - un polímero celulósico soluble en disolventes orgánicos, pero prácticamente insoluble en agua, independientemente de su pH;un polímero metacrílico soluble en medio ácido y prácticamente insoluble a pH neutro o alcalino y un principio activo distribuido de manera homogénea y en estado molecular en la mezcla, la cual se presenta en forma de una matriz atomizada;b) un agente alcalino, de naturaleza orgánica, o una sal alcalina, farmacéuticamente aceptable; y c) un agente adsorbente.2.- Una formulación según la reivindicación 1, caracterizada porque el polímero celulósico y el polímero metacrílico son, respectivamente, etilcelulosa y un polímerocatiónico formado a partir de metacrilato de 2-dimetilaminoetilo y metacrilatos neutros.3.- Una formulación según la reivindicación 1 ó 2, caracterizada porque el agente alcalino y el agente adsorbente se seleccionan, respectivamente, del grupo formado por meglumina, lisina, citratos sódico y de potasio y carbonatos sódico y de potasio, y del grupo formado por silicato de magnesio y de aluminio y talco.4.- Una formulación según la reivindicación 3, caracterizada porque el agente alcalino y el agente adsorbente son, respectivamente, meglumina y silicato de magnesio y de aluminio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0108157A FR2826274B1 (fr) | 2001-06-21 | 2001-06-21 | Formulation pharmaceutique au gout masque et son procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5540278A2 true CO5540278A2 (es) | 2005-07-29 |
Family
ID=8864587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03111139A CO5540278A2 (es) | 2001-06-21 | 2003-12-19 | Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion |
Country Status (42)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7384921B2 (en) * | 2004-02-20 | 2008-06-10 | Enanta Pharmaceuticals, Inc. | Polymorphic forms of 6-11 bicyclic ketolide derivatives |
| GB2419094A (en) | 2004-10-12 | 2006-04-19 | Sandoz Ag | Pharmaceutical composition of unpleasnt tasing active substances |
| FR2882522B1 (fr) * | 2005-02-25 | 2007-04-13 | Aventis Pharma Sa | Composition pharmaceutique solide comprenant de la telithromycine |
| US7384922B2 (en) * | 2005-05-04 | 2008-06-10 | Enanta Pharmaceuticals, Inc. | 6-11 bridged oxime erythromycin derivatives |
| US20060264386A1 (en) * | 2005-05-17 | 2006-11-23 | Rongqi Sun | Pharmaceutical formulations of 6-11 bicyclic ketolide derivatives and related macrolides and methods for preparation thereof |
| KR101387249B1 (ko) * | 2006-02-03 | 2014-05-21 | 에보니크 룀 게엠베하 | 물에 난용성인 유효 성분과 중합체의 혼합물을 함유하는제약 조성물 |
| US20100226979A1 (en) * | 2006-03-21 | 2010-09-09 | Jubilant Organosys Limited | Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate |
| US20080181932A1 (en) * | 2007-01-30 | 2008-07-31 | Drugtech Corporation | Compositions for oral delivery of pharmaceuticals |
| KR100935893B1 (ko) * | 2007-09-11 | 2010-01-07 | 국방과학연구소 | 1,1'-다이메틸-5,5’-바이테트라졸의 합성방법 |
| WO2009055557A1 (en) | 2007-10-25 | 2009-04-30 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| WO2010069330A2 (en) | 2008-12-16 | 2010-06-24 | Carlsberg A/S | Coating of hydroxylated surfaces by gas phase grafting |
| CA2868262A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
| DE102012014848A1 (de) * | 2012-07-27 | 2012-10-31 | Heilerde-Gesellschaft Luvos Just GmbH & Co. KG | Heilerde-Zubereitung |
| KR20170039689A (ko) * | 2014-08-05 | 2017-04-11 | 셈프라 파마슈티컬스, 인크. | 항균제의 분말 경구 현탁제 제형 |
| CN114209661B (zh) * | 2022-02-21 | 2022-04-29 | 北京罗诺强施医药技术研发中心有限公司 | 呈细粒形式的固体药物组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2930409A1 (de) * | 1979-07-26 | 1981-02-12 | Bayer Ag | Spruehtrocknung von mikrokapseldispersionen |
| JPS63150220A (ja) * | 1986-12-15 | 1988-06-22 | Dainippon Pharmaceut Co Ltd | 経口用固形製剤の製造方法 |
| US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
| US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
| ZA945944B (en) * | 1993-08-13 | 1996-02-08 | Eurand America Inc | Procedure for encapsulating nsaids |
| AUPN969796A0 (en) * | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
| EP1027036A2 (en) * | 1997-10-03 | 2000-08-16 | ELAN CORPORATION, Plc | Taste masked formulations |
| IN191239B (es) * | 1999-06-11 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| KR100502031B1 (ko) * | 2000-08-22 | 2005-07-25 | 바실리어 파마슈티카 아게 | 항균 활성을 갖는 신규한 매크롤라이드 |
-
2001
- 2001-06-21 FR FR0108157A patent/FR2826274B1/fr not_active Expired - Fee Related
-
2002
- 2002-05-08 TW TW091109613A patent/TWI228049B/zh not_active IP Right Cessation
- 2002-05-09 JO JO200241A patent/JO2325B1/en active
- 2002-06-11 GT GT200200115A patent/GT200200115A/es unknown
- 2002-06-11 GT GT200200115AK patent/GT200200115AA/es unknown
- 2002-06-17 MY MYPI20022250A patent/MY134340A/en unknown
- 2002-06-18 UY UY27341A patent/UY27341A1/es not_active Application Discontinuation
- 2002-06-18 PE PE2002000522A patent/PE20030201A1/es not_active Application Discontinuation
- 2002-06-19 AR ARP020102300A patent/AR036096A1/es not_active Application Discontinuation
- 2002-06-19 PA PA20028548301A patent/PA8548301A1/es unknown
- 2002-06-19 SV SV2002001098A patent/SV2003001098A/es not_active Application Discontinuation
- 2002-06-21 ES ES02764922T patent/ES2236574T3/es not_active Expired - Lifetime
- 2002-06-21 IL IL15940402A patent/IL159404A0/xx active IP Right Grant
- 2002-06-21 AU AU2002329311A patent/AU2002329311B2/en not_active Ceased
- 2002-06-21 OA OA1200300340A patent/OA12635A/fr unknown
- 2002-06-21 UA UA2004010425A patent/UA77960C2/uk unknown
- 2002-06-21 HU HU0400799A patent/HUP0400799A3/hu unknown
- 2002-06-21 JP JP2003506872A patent/JP4880871B2/ja not_active Expired - Fee Related
- 2002-06-21 TN TNPCT/FR2002/002158A patent/TNSN03141A1/fr unknown
- 2002-06-21 AT AT02764922T patent/ATE290366T1/de active
- 2002-06-21 PL PL366803A patent/PL202090B1/pl unknown
- 2002-06-21 PT PT02764922T patent/PT1401397E/pt unknown
- 2002-06-21 BR BRPI0208998A patent/BRPI0208998A2/pt not_active IP Right Cessation
- 2002-06-21 CA CA2452239A patent/CA2452239C/fr not_active Expired - Fee Related
- 2002-06-21 EA EA200400061A patent/EA006016B1/ru not_active IP Right Cessation
- 2002-06-21 AP APAP/P/2003/002927A patent/AP1595A/en active
- 2002-06-21 SK SK1592-2003A patent/SK285865B6/sk not_active IP Right Cessation
- 2002-06-21 CN CNB028121465A patent/CN1239149C/zh not_active Expired - Fee Related
- 2002-06-21 CZ CZ20033441A patent/CZ299947B6/cs not_active IP Right Cessation
- 2002-06-21 NZ NZ530042A patent/NZ530042A/en not_active IP Right Cessation
- 2002-06-21 MX MXPA03011756A patent/MXPA03011756A/es active IP Right Grant
- 2002-06-21 EP EP02764922A patent/EP1401397B1/fr not_active Expired - Lifetime
- 2002-06-21 DE DE60203178T patent/DE60203178T2/de not_active Expired - Lifetime
- 2002-06-21 WO PCT/FR2002/002158 patent/WO2003000225A2/fr active IP Right Grant
-
2003
- 2003-12-05 ZA ZA2003/09479A patent/ZA200309479B/en unknown
- 2003-12-12 US US10/735,538 patent/US7138138B2/en not_active Expired - Lifetime
- 2003-12-15 NO NO20035581A patent/NO332258B1/no not_active IP Right Cessation
- 2003-12-16 IL IL159404A patent/IL159404A/en not_active IP Right Cessation
- 2003-12-16 MA MA27445A patent/MA27042A1/fr unknown
- 2003-12-16 BG BG108458A patent/BG66314B1/bg unknown
- 2003-12-18 EC EC2003004915A patent/ECSP034915A/es unknown
- 2003-12-19 HR HR20031067A patent/HRP20031067B1/xx not_active IP Right Cessation
- 2003-12-19 CO CO03111139A patent/CO5540278A2/es active IP Right Grant
-
2005
- 2005-01-07 HK HK05100110A patent/HK1067558A1/xx not_active IP Right Cessation
-
2006
- 2006-09-20 US US11/533,573 patent/US20070014857A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5540278A2 (es) | Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion | |
| KR101715008B1 (ko) | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 | |
| ES2542728T3 (es) | Composiciones farmacéuticas que tienen la biodisponibilidad deseable | |
| ES2282062T1 (es) | Composicion farmaceutica que contiene irbesartan. | |
| CR9704A (es) | Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma. | |
| CO6150127A2 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| RU2012101818A (ru) | Наноструктурированное основание силденафила, его фармацевтически приемлемые соли и со-кристаллы, их композиции, способ их получения и содержащие их фармацевтические композиции | |
| AR027179A1 (es) | Formulas farmaceuticas liquidas de sabor enmascarado | |
| PA8509001A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| JP2008501802A5 (es) | ||
| RU2003132426A (ru) | Фармацевтический раствор арипипразола для орального применения | |
| ES2311442T1 (es) | Dosis en forma oral. | |
| ATE429416T1 (de) | Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen | |
| CN101636152A (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
| JP2009544722A5 (es) | ||
| JP2005523313A (ja) | 目の酒さ及び酒さ性ざ瘡の同時治療方法 | |
| PE20051163A1 (es) | Formas de dosificacion oral de acido n-(2-(2-ftalimido-etoxi)-acetil)-l-alanil-d-glutamico (lk 423) | |
| ES2224917T1 (es) | Composiciones farmaceuticas de agente fibrinolitico. | |
| JP5232641B2 (ja) | 新規なアセチルサリチル酸製剤 | |
| ES2584534A1 (es) | Formulación tópica oftálmica de bosentan | |
| CA2333188C (fr) | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation | |
| RU2011135417A (ru) | Галеновы препараты органических соединений | |
| WO2017190714A1 (es) | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular | |
| ES2460967T3 (es) | Método para la prevención de la degradación de una sustancia térmicamente inestable | |
| RU2008151945A (ru) | Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |